Biochemical Basis of Prolidase Deficiency

Polypeptide and RNA Phenotypes and the Relation to Clinical Phenotypes

Fumio Endo,* Akito Tanoue,* Akito Kitano,* Jiro Arata,§ David M. Danks,§ Charles M. Lapière,§ Yoshinori Sei,§ Sybe K. Wadman,* and Ichiro Matsuda*

*Department of Pediatrics, Kumamoto University Medical School, Kumamoto, Japan; §Department of Dermatology, Okayama University Medical School, Okayama, Japan; §The Murdoch Institute, Royal Children’s Hospital, Victoria, Australia; §Department of Dermatology, University of Liège, Liège, Belgium; §Department of Dermatology, Kanazawa Medical University, Uchinada, Japan; and **Wilhelmina Children's Hospital, Utrecht, The Netherlands

Abstract

Cultured skin fibroblasts or lymphoblastoid cells from eight patients with clinical symptoms of prolidase deficiency were analyzed in terms of enzyme activity, presence of material crossreacting with specific antibodies, biosynthesis of the polypeptide, and mRNA corresponding to the enzyme. There are at least two enzymes that hydrolyze imidodipeptides in these cells and these two enzymes could be separated by an immunochemical procedure. The specific assay for prolidase showed that the enzyme activity was virtually absent in six cell strains and was markedly reduced in two (< 3% of controls). The activities of the labile enzyme that did not immunoprecipitate with the anti-prolidase antibody were decreased in the cells (30–60% of controls).

Cell strains with residual activities of prolidase had immunological polypeptides crossreacting with a M, 56,000, similar to findings in the normal enzyme. The polypeptide biosynthesis in these cells and the controls was similar. Northern blot analyses revealed the presence of mRNA in the polypeptide-positive cells, yet it was absent in the polypeptide-negative cells. The substrate specificities analyzed in the partially purified enzymes from the polypeptide-positive cell strains differed, presumably due to different mutations. Thus, there seems to be a molecular heterogeneity in prolidase deficiency.

There was no apparent relation between the clinical symptoms and the biochemical phenotypes, except that mental retardation was present in the polypeptide-negative patients. The activities of the labile enzyme may not be a major factor in modifying the clinical symptoms. (J. Clin. Invest. 1990. 85:162–169.) biosynthesis • crossreacting materials • deficiency • mRNA • peptidase • prolidase

Introduction

Prolidase deficiency is an autosomal recessive disorder characterized by mental retardation, various skin lesions, and abnormalities of collagenous tissues (1). Prolidase catalyzes hydrolysis of di- and tripeptides with carboxy-terminal proline and seems to play an important role in the recycling of proline. As a consequence of the deficiency of prolidase, massive imidodipeptiduria and relatively lowered levels of plasma proline are present in the patients (1). The precise mechanisms involved in the development of skin lesions, mental retardation, and other symptoms including splenomegaly, osteoporosis, and frequent infections have not been completely elucidated.

More than 20 cases of prolidase deficiency have been reported, and some of the patients had no clinical symptoms of the disease (2, 3). The symptoms do not seem to be related to severities produced by the enzyme defect, as deduced from individual case reports. Clinical symptoms appear gradually; hence, an assessment of the symptoms at the time of the diagnosis or during the relatively short period of the investigations is difficult. The hydrolytic activities toward imidodipeptides in crude extracts of tissues and cells may not solely represent the activity of a single enzyme (4) and activities of prolidase in cases of a deficiency may not reflect residual activities of prolidase itself, which is genetically defective.

We purified human prolidase to apparent homogeneity and prepared anti-prolidase monoclonal and polyclonal antibodies for use in the immunochemical analysis of prolidase deficiency (5). Boright et al. (6) most recently developed a polyclonal antibody directed against prolidase and used it to analyze cells from prolidase-deficient patients. We used the antibodies to identify a cDNA clone corresponding to the human prolidase mRNA (7). Based on the partial amino acid sequence of the purified enzyme and the nucleotide sequence of the cDNA clones, the primary structure of human prolidase has been deduced (8).

We have now examined the biochemical basis of prolidase deficiency using cultured skin fibroblasts or cultured lymphoblastoid cells obtained from subjects from families with prolidase deficiency. The availability of the specific antibodies and the cloned cDNA facilitated a definition of the polypeptide and RNA phenotypes of these patients. The biochemical and clinical phenotypes were compared.

Methods

Materials. IgG-EP2, EP10, and EP38 mouse MAbs that bind to human prolidase, and IgG-NR, a control mouse MAb directed against an irrelevant antigen, were prepared by the hybridoma technique described elsewhere (5). Human prolidase was then purified from peripheral erythrocytes using an immunoaffinity gel (9). Polyclonal antiserum was developed in rabbits by injecting purified human prolidase. Prolidase-Sepharose 4B was prepared using cyanogen bromide-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) according to the manufacturer’s description. The gel preparation containing 2 mg of purified prolidase per ml of Sepharose 4B was used to isolate the
specific IgG that binds to prolidase from the anti-prolidase rabbit serum. Immobilized mouse IgGs on agarose beads were prepared using purified IgGs and cyanogen bromide-activated Sepharose 4B (1 mg of purified IgG per ml).

The CDNA insert (PL-21) corresponding to human prolidase mRNA was cloned and characterized (8). It was found to cover nearly the full length of the coding region and 3' noncoding region of the mRNA and was used as a probe for RNA blotting analysis. The DNA probe was radiolabeled as described (10). [α-35S]CTP (3,000 Ci/mmol) and [35S]methionine (1,100 Ci/mmol) were purchased from ICN radiochemicals (Irvine, CA). Nitrocellulose membranes were obtained from Schleicher and Schuell (Dassel, FRG).

Preparation of cell extracts. Confluent cultured monolayers of skin fibroblasts cultured as described (11) were collected by a rubber policeman and washed three times with PBS. The cell pellets were suspended in ice-cold PBS and then disrupted by sonication (Handy Sonic UR-20P; Tomy Seiko Co. Ltd., Tokyo, Japan). The EBV-transformed lymphoblastoid cells were cultured as described (12), washed three times with PBS, and sonicated. The disrupted cells were centrifuged at 12,000 g for 3 min and the supernatants were used for further analyses.

Immunoblot analyses. The extracts (100 μg protein) were mixed with a 50 μL of 1:1 suspension that contained covalently bound mouse monoclonal IgGs to immunoprecipitate the prolidase. The suspensions were incubated for 1 h at room temperature on an end-to-end rotor, centrifuged, and the pellets washed three times with 1 mL of ice-cold 50 mM Tris-HCl buffer, pH 7.0. Finally, the pellets were mixed with an equal volume of 125 mM Tris-HCl, pH 6.8, 4% SDS (wt/vol), 10% (vol/vol) glycerol, and 2% (vol/vol) mercaptoethanol. The suspensions were placed in a boiling water bath for 1 min, cooled at room temperature, and centrifuged. A sample of the supernatant was subjected to SDS-PAGE. Alternatively, the cell extracts (100 μg protein) were directly subjected to SDS-PAGE. Transfer of proteins to nitrocellulose membranes was done according to Towbin et al. (13). The nitrocellulose membranes were incubated with 0.5–1 μg/mL anti-prolidase rabbit IgG. The rabbit IgG was detected as described (5).

Analysis of [35S]methionine-labeled prolidase. Confluently cultured fibroblasts in 75-cm2 flask were precultivated in 5 ml methionine-free medium including 10% dialyzed FCS (Gibco Laboratories, Grand Island, NY) for 60 min and then pulse-labeled with [35S]methionine (100 μCi) at 37°C in 4 ml of the same medium. Similarly, cultured lymphoblastoid cells (101) were precultivated in 2 ml of methionine-free medium for 2 h at 37°C in 5% CO2 and pulse-labeled with [35S]methionine in a total vol of 4 ml. The cells were washed with ice-cold PBS lysed by sonication in a buffer containing 50 mM Tris HCl, pH 7.4, 0.1% Triton X-100, 2 mM PMSF, 10 μg/mL leupeptin, and 0.1 mg/mL aprotinin.

Immunoprecipitation of labeled prolidase with the polyclonal antibody was carried out as follows. An amount of rabbit IgG sufficient to precipitate labeled prolidase was added to the supernatant of the cultured cells. The mixture was incubated at 37°C for 60 min, then 50 μL of the suspension of protein A–agarose (50% vol/vol; Pharmacia) was added. The incubation was continued for 60 min at room temperature on the end-to-end rotor. At the end of the incubation the gel was washed three times with 1 ml of 50 mM Tris-HCl, pH 7.0, containing 0.1% Triton X-100, 0.05% SDS, and protease inhibitors. The immunoprecipitates were separated by SDS-PAGE and the gels were analyzed by fluorography.

SDS-PAGE. Electrophoresis of proteins was carried out in 10% polyacrylamide gels containing 0.1% SDS (14). Gels were calibrated with the following molecular weight standards: phosphorylase b, 92,500; BSA, 66,000; ovalbumin, 43,000; and catalase, 35,000. For the fluorography, each slab gel was soaked in ENHANCE (New England Nuclear, Boston, MA) for 1 h at room temperature, washed for 30 min with cold distilled water, dried, and placed in contact with an x-ray film (Kodak X-Omat) at ~70°C for 36–120 h.

RNA blot analysis. Total RNA was isolated from the cultured cells by a guanidine thiocyanate procedure and analyzed by blotting after electrophoresis in formamide-containing agarose gels (1%) as described (15). Conditions for hybridization and washing were as described (8).

Enzyme assay. Imidodipeptide-hydrolyzing activities were measured using glycy-L-proline, L-alanyl-L-proline, and L-leucyl-L-proline as substrates. The activities in the crude cell extracts were measured at 37°C in a total vol of 250 μL containing 0.1 M Tris-HCl, pH 8.0, 10 mM MnCl2, and 10 mM of a substrate peptide after 15 min of preincubation unless otherwise stated. The prolidase released from the peptides was assayed by the method of Chiniard (16) as described (17).

For the immune titration of prolidase activity, various amounts of mouse or rabbit IgG were incubated with the crude cell extracts for 1 h at room temperature and a 50-μl suspension of protein A agarose (1:1) was added. The enzyme activity in the supernatant was then measured. The enzyme activity that bound to mouse IgG EP2 was measured as follows: the samples were prepared by incubating the crude cell extracts and EP2-agarose at room temperature for 1 h. The gel was washed three times with 50 mM Tris-HCl, pH 7.6, containing 10 mM MnCl2. The gel suspension was preincubated for 15 min at 37°C and the substrate peptides were added. After an appropriate incubation time at 37°C, with vigorous shaking, the supernatant was collected and used for the determination of prolidase. Mouse IgG EP2 did not inhibit the enzyme activity of prolidase. Alternatively, the prolidase was eluted from the gel with 0.1 M Na2CO3 for enzyme assay (9).

Patients. Cultured skin fibroblasts or cultured lymphoblastoid cells were obtained from eight patients with prolidase deficiency. Clinical features are summarized in Table I. Two patients died (cases 2 and 4) and skin lesions were present in all the patients. In severe cases there were deep skin ulcers or lymphedema. Mild skin lesions included eruption, telangiectasia, and pigmentation. Two of the first cousins of the case 5 patient had a prolidase deficiency with similar skin lesions and other clinical features. Skin lesions of the case 7 patient were present from 19 mo, while her sister (case 8) had no prominent changes in the skin until 18 yr.

Results

Fig. 1 A shows the immune titration of imidodipeptide-hydrolyzing activities with mouse IgG EP2 in crude extracts from a control fibroblast cell strain. Most of the imidodipeptide-hydrolyzing activity was immunoprecipitated. When the enzyme activity in the supernatant was measured without preincubation a small amount of activity was detected (Tables II and III). This activity remained in the supernatant after immunoprecipitation with the polyclonal rabbit IgG or other monoclonal mouse IgGs (EP10 and EP38). The activity of prolidase was not inhibited when mouse IgG-EP2 was added to the mixture (Fig. 1 A). As described below, the substrate specificities of the activities in the supernatant and in the immunoprecipitates differed. L-Alanyl-L-proline was used as a substrate in this experiment, since this peptide was suitable to detect both activities.

Immunoblot analyses of the immunoprecipitated fraction and the supernatant obtained from the control cells are shown in Fig. 1 B. The precipitate contained a protein of M, 56,000 that crossreacted with the polyclonal antibody. The supernatant, however, did not. The M, 56,000 protein was the subunit derived from prolidase (5, 9). The imidodipeptide-hydrolyzing activity in the supernatant showed a different substrate specificity from the immunoprecipitated enzyme (Table II). The enzyme activity in the supernatant seemed to correspond to the labile enzyme reported by Butterworth and Priestman (4). The labile enzyme could be separated from prolidase by DEAE cellulose column chromatography (4). We confirmed that the labile enzyme did not crossreact with antiprolidase monoclo-
Table I. Clinical Phenotypes of Patients with Prolidase Deficiency

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age</th>
<th>Onset of symptoms</th>
<th>Initial symptoms</th>
<th>Clinical symptoms</th>
<th>Consanguinity (family history)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>8</td>
<td>Early infancy</td>
<td>Skin, hypotonia</td>
<td>+ − + − −</td>
<td>Moderate (−)</td>
<td>26</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>Died at 36</td>
<td>7 yr</td>
<td>Skin, splenomegaly</td>
<td>+ − − +</td>
<td>−</td>
<td>27</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>21</td>
<td>3 mo</td>
<td>Skin</td>
<td>+ ± − − +</td>
<td>−</td>
<td>18</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>Died at 15</td>
<td>2 mo</td>
<td>Diarrhea, thrombocytopenia, splenomegaly</td>
<td>+ − − +</td>
<td>−</td>
<td>18</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>38</td>
<td>5–7 yr</td>
<td>Skin</td>
<td>+ + + + +</td>
<td>+</td>
<td>28, 29</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>18</td>
<td>10 yr</td>
<td>Skin</td>
<td>+ − − − +</td>
<td>+</td>
<td>19</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>25</td>
<td>19 mo</td>
<td>Skin</td>
<td>+ − − − +</td>
<td>+</td>
<td>30</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>18</td>
<td>18 yr</td>
<td>Skin</td>
<td>+ − − − +</td>
<td>+</td>
<td>30</td>
</tr>
</tbody>
</table>

MR, mental retardation; BJ, abnormalities of bones and joints.

Figure 1. Presence of imidopeptide-hydrolyzing activity not immunoprecipitated with anti-prolidase monoclonal mouse IgG-EP2 in the crude extract of control fibroblasts. The crude extract from control fibroblasts was subjected to immunoprecipitation with EP2 and protein A–agarose. A. The imidopeptide-hydrolyzing activities were measured in the supernatant after immunoprecipitation (○, ●) or in the mixture before the addition of protein A–agarose (×). The activities were measured as described in Methods (○, ×) or without preincubation (●). Reactions were carried out in the presence of MnCl₂ in both assays and as described in Methods. 50 mM L-Alanyl-L-proline was used as the substrate. The activities were expressed by percentage of the initial ones. B. The immunoprecipitate and the supernatant obtained with 1,000 ng of mouse IgG were analyzed for the subunit of prolidase by means of prolidase of immunoblotting. Lane a, immunoprecipitate; b, supernatant. The subunit of prolidase was detected using anti-prolidase rabbit IgG as described in Methods. Note that the subunit of prolidase (M₀ 56,000) is specifically stained in lane a.

Table II. Enzymic Activities of the Prolidase and the Labile Enzymes in Cultured Skin Fibroblasts

<table>
<thead>
<tr>
<th>Case</th>
<th>Controls*</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Prolidase (immunoprecipitated with EP2)</td>
<td>Gly-pro</td>
<td>139.3±10.6</td>
<td>4.2</td>
<td>1.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ala-pro</td>
<td>74.6±6.2</td>
<td>1.5</td>
<td>1.2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leu-pro</td>
<td>54.6±7.1</td>
<td>1.8</td>
<td>4.2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Labile enzyme (supernatant)</td>
<td>Gly-pro</td>
<td>9.2±3.8</td>
<td>3.4</td>
<td>2.9</td>
<td>4.4</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ala-pro</td>
<td>16.2±5.3</td>
<td>5.6</td>
<td>4.4</td>
<td>8.2</td>
<td>3.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leu-pro</td>
<td>8.3±2.4</td>
<td>3.4</td>
<td>0.7</td>
<td>5.2</td>
<td>2.8</td>
</tr>
</tbody>
</table>

* Control values are from three cell strains (mean±SD). Other values are the mean of triplicate determinations. Prolidase activities were measured using immune precipitates as a source of the enzyme. Activities remaining in the supernatant after immunoprecipitation are referred to as the labile enzyme. Activities of the labile enzyme were assayed without preincubation. Enzymic activities were expressed as nanomoles/milligram protein per minute. Other conditions of the assay are described in Methods.
precipitated by mouse IgG-EP2 (Table II). In cases 3–8 no activity was immunoprecipitated. The remaining imidodipeptide-hydrolyzing activities in the supernatant from these cells was not immunoprecipitated by adding polyclonal antibody (not shown). These immunochromatographic studies on human cultured fibroblasts and lymphoblastoid cells confirmed that there are at least two different enzymes that hydrolyze imidodipeptides. The major enzyme, prolidase, was impaired in cells from prolidase-deficient subjects. The supernatant activity from the patients’ cells preferentially hydrolyzed L-alanyl-L-proline as was demonstrated in the control cells; however, the activities were lower than in the control (30–60% of control; Tables II and III).

The immune complexes prepared with EP2-agarose and the crude extracts of the cell strains of cases 1 and 2 contained imidodipeptide-hydrolyzing activity (Table II). The enzyme from case 1 preferentially hydrolyzed glycyL-L-proline and the enzyme from case 2, L-leucyl-L-proline (Table II). These activities seemed to represent the mutant enzymes in these two cell strains. The activity associated with EP2-agarose could be eluted with 0.1 M Na₂CO₃ without loss of the activity. The putative-mutant enzymes were eluted from EP2-agarose and studied for substrate specificities. The activities and the substrate specificities of the enzymes in each cell strain were similar to those obtained using immune complexes (not shown).

Immune proteins precipitated with EP2-agarose from the cultured fibroblasts and lymphoblastoid cells were studied by immunoblotting (Fig. 2, A, C, and E). In the lane related to control cells, a protein with Mr, 56,000 was specifically stained. Samples from cases 1 and 2 contained immunologically crossreacting materials (CRM).¹ Size of the CRM were the same as that of the control. In other experiments the crude extracts of the cultured cells were analyzed directly by immunoblotting (Fig. 2, B, D, and F). These results suggest that cells from cases 3–8 patients did not contain CRM when examined using immunoblots. An analysis of erythrocytes from the case 6 patient revealed the absence of CRM (not shown).

Metabolic labeling of the fibroblasts followed by immunoprecipitation of prolidase was done to investigate the biosynthesis of prolidase. When control cells were pulse-labeled for 1 h a protein with Mr, 56,000 was recognized (Fig. 3). The molecular mass of this labeled protein did not change during a 1-h chase. Thus, the subunit of prolidase was synthesized as a polypeptide with Mr, 56,000, findings similar to those for the mature enzyme. No major processing occurred.

The fibroblast cell strains and the lymphoblastoid cells from patients with a prolidase deficiency (except for cases 7 and 8) were analyzed by metabolic labeling (Fig. 4). Cell strains from cases 1 and 2 synthesized a polypeptide with Mr, 56,000; however, the other strains synthesized no immunologically crossreacting polypeptide. The results of immunoblot analyses and metabolic labeling experiments suggested that cell strains from cases 3, 4, 5, and 6 either did not synthesize CRM or synthesized only an unstable polypeptide.

Northern blot hybridization was used to determine prolidase gene expression in the fibroblast cell strains and lymphoblastoid cell strains (Fig. 5). A cDNA insert that covered most of the coding region and the 3’ noncoding region was radiolabeled and used as a probe. In the lane containing the total RNA from the control cells a 2.3-kb band was observed. Lanes that contained the same amount of total RNA showed a radiolabeled band of the same size (cases 1 and 2). On the other hand, mRNA corresponding to prolidase was not detected in cells from other patients. RNA preparations from the fibroblast strains of cases 7 and 8 were not available.

Thus, we analyzed eight cell strains from seven families with clinically manifested prolidase deficiency. Two were CRM positive and the others were CRM negative. CRM-positive cell strains possessed weak but detectable activities of prolidase. CRM-negative cell strains were mRNA negative. The biochemical phenotypes are summarized in Table IV.

Discussion

Our series of experiments revealed that human prolidase is a homodimer with an estimated Mr, 56,000 as determined by SDS-PAGE (5, 9), and the subunit composed of 492 amino acid residues has an Mr, of 54,305 (8). The cDNA codes 493 amino acid residues, and in the mature enzyme the NH₂-terminal methionine is removed and the newly appearing NH₂-terminal alanine is acetylated, probably acetylated (8). There is no evident processing on the carboxyl terminus and there are two possible glycosylation sites on the polypeptide (8). We observed biosynthesis of prolidase within fibroblasts and lymphoblasts from controls. Pulse and chase experiments revealed that the subunit of prolidase is synthesized as a polypeptide with Mr, 56,000, similar to findings with the purified enzyme (5, 9). These findings are compatible with data obtained in studies on fibroblasts (6). All these results suggest that both the processing of the polypeptide (as expected from the previous study) and glycosylation were minimal.

We reported that the subunit protein of prolidase was absent in erythrocytes of a Japanese subject with prolidase deficiency (5). The subunit protein and the corresponding mRNA in the cultured lymphoblastoid cells from the same patient were absent (case 5). In addition, we analyzed both the erythrocytes and the cultured lymphoblastoid cells from the case 6 patient and noted that CRM was absent in both types of cells. mRNA was absent in the lymphoblastoid cells from the case 6 patient. These results suggest that genetic defects in prolidase deficiency are equally expressed in these cells.

Table III. Enzymic Activities of the Prolidase and the Labile Enzyme in Cultured Lymphoblastoid Cells

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Case 3</th>
<th>Case 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolidase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly-pro</td>
<td>66.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ala-pro</td>
<td>27.4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leu-pro</td>
<td>23.1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Labile enzyme (supernatant)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly-pro</td>
<td>7.6</td>
<td>4.1</td>
<td>4.8</td>
</tr>
<tr>
<td>Ala-pro</td>
<td>15.3</td>
<td>7.1</td>
<td>6.6</td>
</tr>
<tr>
<td>Leu-pro</td>
<td>7.2</td>
<td>4.4</td>
<td>2.1</td>
</tr>
</tbody>
</table>

Values are the mean of triplicate determinations. The enzymic activities are expressed as nanomoles/milligram protein per minute. Prolidase and the labile enzyme were separated and measured as described in the footnote to Table I and in Methods.

¹ Abbreviation used in this paper: CRM, crossreacting materials.
The genetic heterogeneity in prolidase deficiency was demonstrated by the specific assay of prolidase, immunoblot, and metabolic labeling analyses of the enzyme protein, and analyses of mRNA by Northern blotting in the cultured cells. Two of the eight patients were CRM positive. In the two CRM-positive cell strains, biosynthesis of the polypeptides was similar to that of control; hence, there may be a single amino acid substitution among the mutant enzymes. These results are in accord with those obtained from immunoblot analyses in which the decreased amount of the M, 56,000 polypeptide was specifically demonstrated in both cell types. Northern blots revealed a normal size of mRNAs in both cell types. The difference in substrate specificities seen with the two mutant enzymes may indicate different mutations, although the active site of the enzyme does relate to both mutations. Boright et al. (6) reported a case with high molecular weight polypeptide that crossreacted with anti-prolidase antibody. These data indicate that a genetic heterogeneity is present among the CRM-positive patients.

These studies support the proposal that prolidase deficiency is caused by a genetic defect within the prolidase gene. Prolidase deficiency is a syndrome characterized by a variety of abnormalities in organs and tissues. One of the main questions is whether the disorder is caused by a defect in the prolidase gene or whether another gene is involved. Prolidase was absent in the mRNA in four patients with prolidase deficiency. Thus, the defect in the protein might be associated with a defect in expression of the gene. The abnormal enzymes in two patients suggest that the mutations might be localized at the prolidase gene.

Severities of enzyme defects have been speculated, based on results of prolidase assays with extracts from cells including peripheral erythrocytes (2, 3, 17–21), leukocytes (21, 22), cultured skin fibroblasts (4, 18, 23, 24), and cultured lymphoblastoid cells (18). However, human cells contain a labile activity other than prolidase toward imidodipeptides (4, 23) and levels of the labile activity vary with the cell and tissue (4). As a specific assay of prolidase was required to assess severity of the enzyme defects, we made use of an immunochemical procedure described in Methods. The following samples were analyzed: A and B, cultured skin fibroblasts from control and cases 1–4. C and D, cultured lymphoblastoid cells from control and cases 5 and 6. E and F, cultured skin fibroblasts from control and cases 7 and 8. Cases 7 and 8 were siblings. Arrows indicate size of the subunit of prolidase, M, 56,000.
Figure 4. Biosynthesis of the subunit of prolidase in cultured skin fibroblasts or cultured lymphoblastoid cells from patients with prolidase deficiency and from controls. The cultured skin fibroblasts (A) or the cultured lymphoblastoid cells (B) were pulse-labeled with [35S]methionine for 6 h and chased for 1 h. The cell extracts were treated with the affinity-purified rabbit IgG or preimmune IgG. The immunoprecipitates were analyzed as described in Methods. The black arrows indicate the size of the subunit of prolidase, Mr 56,000. The nonspecifically precipitated protein is indicated by the white arrow.

The age at onset of the clinical symptoms did not correlate with the severity of the enzyme defect. The mental development possibly reflects the severity of the biochemical defect since mental retardation occurred only in the CRM-negative patients; however, the absence of CRM is not always associated with mental retardation. The mutant prolidases in the CRM-positive cells showed low levels of enzyme activity, but this residual activity may be too minimal to alter imidodipeptide metabolism in the skin and collagenous tissues.

The labile enzyme probably plays some role in metabolism of the imidodipeptides. Our study provided evidence that the labile enzyme is not immunologically related to prolidase. These two enzymes, the prolidase and the labile enzyme, represent different polypeptides; hence, the structural gene must be different.

Butterworth and Priestman (4) described abnormal natures of the labile enzyme in prolidase-deficient cells. Boright et al. (6) reported that the hydrolyzing activity against glycyl-L-proline was ~5% normal in CRM-negative cells, thereby indicating the presence of the labile enzyme. Our approaches, presented in this study, facilitated assessment of the activity of the labile enzyme even in the control and the CRM-positive cells. Our data show that the labile activities are equally decreased in CRM-positive and -negative cells. However, these enzyme assays do not allow for estimation of the total imidodipeptide-hydrolyzing activity in vivo in the patients and the control.

An interpretation for the decreased activities of the labile enzyme in the patients' cells is difficult since knowledge of the

Figure 5. Northern blot analyses of RNA obtained from cultured skin fibroblasts and the cultured lymphoblastoid cells. Total RNA was prepared and analyzed as described in Methods. Each lane contained 10 μg of total RNA obtained from cultured skin fibroblasts (lanes a–e) or cultured lymphoblastoid cells (lanes f–h). Lanes a and f, control; b, case 1; c, case 2; d, case 3; e, case 4; g, case 5; h, case 6. The arrow indicates the size of mRNA corresponding to the subunit of prolidase (2.3 kb).
Table IV: Biochemical Phenotypes of Cells from Patients with Prolidase Deficiency

<table>
<thead>
<tr>
<th>Case</th>
<th>Cells</th>
<th>Prolidase activity</th>
<th>Immunoblot</th>
<th>Biosynthesis</th>
<th>mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Fibroblasts</td>
<td>~3% of control</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
</tr>
<tr>
<td>2</td>
<td>Fibroblasts</td>
<td>0.7–7.6% of control*</td>
<td>Absent</td>
<td>Present</td>
<td>Present</td>
</tr>
<tr>
<td>3</td>
<td>Fibroblasts</td>
<td>0</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>4</td>
<td>Fibroblasts</td>
<td>0</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>5</td>
<td>Lymphoblastoid cells</td>
<td>0</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>6</td>
<td>Erythrocytes</td>
<td>0</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>7</td>
<td>Fibroblasts</td>
<td>0</td>
<td>Absent</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>8</td>
<td>Fibroblasts</td>
<td>0</td>
<td>Absent</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

* Range of enzymatic activities against different substrate peptides.

labile enzyme is limited. Butterworth and Priestman speculated, based on their observations, that the labile enzyme and prolidase might possess a common subunit (4). However, our observations ruled out this possibility. We assume that prolidase may be related to the stability of the labile enzyme in vivo or that gene regulation of the labile enzyme may be influenced by factors that relate to prolidase activity.

Regarding the clinical heterogeneity of prolidase deficiency, the role of the labile enzyme has to be clarified. It is tempting to speculate that among individuals with a prolidase deficiency and various activities of the labile enzyme, those with decreased levels may develop clinical symptoms of prolidase deficiency. However, our data of the siblings (cases 7 and 8 of prolidase deficiency with different degrees of severity of skin lesions) do not support this proposal. The case 7 patient developed skin lesions at age 19 mo and specific treatment was required, whereas her sister (case 8) had no prominent change in the skin until age 18 yr. Both were CRM negative and there were no residual activities of prolidase in the fibroblasts. The total imidodipeptide-hydrolyzing activities of two cell strains were similar (Table II). The imidodipeptide-hydrolyzing activities in sera of siblings was reported to be similar (25). These activities in the sera may represent the labile enzyme since these two patients were CRM negative and the substrate specificity of the activity resembled that of the labile enzyme (25). The labile enzyme in this family may not itself be a major factor modifying development of skin lesions.

Thus, our data suggest that the labile enzyme seems to be largely irrelevant as a biochemical basis for this metabolic disorder. Further studies are needed to clarify the mechanisms of the heterogeneous expression of the genetic defects in relation to this specific disorder.

Cloning of genomic DNA for the prolidase gene is ongoing in our laboratory. The prolidase gene is extremely large in humans and possible pseudogenes have to be identified (Tanoue, A., F. Endo, and I. Matsuda, manuscript in preparation).

Acknowledgments

We thank Dr. I. Akaboshi for advice on the cell culture, M. Izumida for assistance with the cell cultures, M. Hongo and M. Hayashi for secretarial services, and M. Ohara for helpful comments.

This work was supported in part by a grant in aid from the Ministry of Education of Japan and the Ministry of Health and Welfare and in part by a research grant from IBM Japan and Biotechnology Suisshinkai.

References


